世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

血友病治療市場:タイプ別(血友病A、血友病B)、薬物療法別(遺伝子組換え凝固因子濃縮療法、血漿由来凝固因子濃縮療法、非因子補充療法、その他)。世界の機会分析および産業予測、2021-2031年


Hemophilia Treatment Market By Type (Hemophilia A, Hemophilia B), By Drug Therapy (Recombinant coagulation factor concentrates therapy, Plasma derived coagulation factor concentrates therapy, Non-factor replacement therapy, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

世界の血友病治療市場は、2021年に127億6480万ドルと評価され、2031年には269億520万ドルに達すると予測され、2022年から2031年までのCAGRは7.5%を記録しています。 血友病は通常、遺伝性の出血性疾患で、血液が... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Allied Market Research
アライドマーケットリサーチ
2022年6月30日 US$5,769
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
198 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

世界の血友病治療市場は、2021年に127億6480万ドルと評価され、2031年には269億520万ドルに達すると予測され、2022年から2031年までのCAGRは7.5%を記録しています。
血友病は通常、遺伝性の出血性疾患で、血液が適切に凝固しない病気です。このため、怪我や手術に続いて、自然出血を起こすことがあります。血液には凝固因子と呼ばれるタンパク質が多く含まれており、この凝固因子が出血を止めるのに役立ちます。血友病の人は、第VIII因子または第IX因子の濃度が低い。血友病の重症度は、血液中の因子の量によって決定されます。血友病は、血栓を形成するために必要な凝固因子タンパク質を作るための指示を提供する遺伝子の1つで、突然変異または変化によって引き起こされます。血友病には、血友病Aと血友病Bの2種類があります。血友病の治療には、血液が適切に凝固できるように、不足している血液凝固因子を補充することが含まれます。これは、市販の濃縮因子を静脈から投与する点滴によって行われます。血友病の患者さんは、自分で輸液を行う方法を学ぶことで、出血を止めることができ、定期的に輸液を行うことで、ほとんどの出血を防ぐことも可能です。

世界の血友病治療市場の成長を促進する主な要因としては、血友病の有病率の増加、血友病治療の技術的進歩、血友病管理に対する政府の有利な措置などが挙げられます。また、対象人口の増加、診断率の向上、血友病の予防的治療の増加も市場成長の推進要因となっています。しかし、血友病治療の高コスト、血友病の医薬品の不足、血漿由来製品に関連する重篤な副作用は、市場成長を制限すると予想されます。逆に、発展途上国における血友病に関する認知度の向上は、市場成長のための有利な機会を提供します。
血友病治療市場は、タイプ、薬物療法、地域に基づいて区分されています。タイプ別では、血友病Aと血友病Bに、薬物療法別では、遺伝子組換え凝固因子濃縮療法、血漿由来凝固因子濃縮療法、非因子補充療法、その他に市場が二分されます。地域別では、北米、欧州、アジア太平洋地域、LAMEAで分析されています。
本レポートに掲載されている主要企業は、Bayer AG、Pfizer, Inc.、F. Hoffmann-La Roche AG、CSL Ltd.、武田薬品工業株式会社、Novo Nordisk A/S、Grifols S.A.、スウェーデン孤児Biovitrium AB、Octapharma AGおよびMedexus Pharmaceuticals Inc.です。

ステークホルダーにとっての主なメリット
●本レポートは、2021年から2031年までの血友病治療市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、血友病治療市場の優勢な機会を特定します。
●市場調査は、主要な推進要因、阻害要因、機会に関連する情報とともに提供されます。
ポーターのファイブフォース分析では、買い手と供給者の力関係を明らかにし、利害関係者が利益重視のビジネス決定を下し、供給者と買い手のネットワークを強化できるようにします。
血友病治療市場のセグメンテーションを詳細に分析することで、市場機会を決定することができます。
血友病治療市場に関する詳細な分析は、市場機会を決定するのに役立ちます。
市場プレイヤーのポジショニングは、ベンチマークを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
地域別および世界別の血友病治療市場動向、キープレイヤー、市場セグメント、応用分野、市場成長戦略などの分析が含まれています。

主な市場セグメント
タイプ別
血友病A
血友病B
薬物療法別
遺伝子組換え凝固因子製剤療法
血漿由来凝固因子製剤療法
非因子補充療法
非因子補充療法 ● その他

地域別
北米
米国
カナダ
メキシコ
欧州
ドイツ
フランス
イギリス
イタリア
スペイン
その他の地域
アジア・パシフィック
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
LAMEA
ブラジル
○ 南アフリカ
サウジアラビア
LAMEAの他の地域

主な市場参加者
バイエル
CSL Ltd.(CSLベーリング)
F. ホフマン・ラ・ロシュ社
グリフォルス S.A
メデクサス・ファーマシューティカルズ・インク(Medexus Pharmaceuticals Inc.
○ ノボ ノルディスク A/S
オクタファーマAG
Pfizer Inc.
スウェーデン オーファン バイオビトラム AB
武田薬品工業(株)

ページTOPに戻る


目次

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: HEMOPHILIA TREATMENT MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Hemophilia A
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Hemophilia B
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY
5.1 Overview
5.1.1 Market size and forecast
5.2 Recombinant coagulation factor concentrates therapy
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Plasma derived coagulation factor concentrates therapy
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Non-factor replacement therapy
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Others
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
CHAPTER 6: HEMOPHILIA TREATMENT MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Type
6.2.3 North America Market size and forecast, by Drug Therapy
6.2.4 North America Market size and forecast, by country
6.2.4.1 U.S.
6.2.4.1.1 Market size and forecast, by Type
6.2.4.1.2 Market size and forecast, by Drug Therapy
6.2.4.2 Canada
6.2.4.2.1 Market size and forecast, by Type
6.2.4.2.2 Market size and forecast, by Drug Therapy
6.2.4.3 Mexico
6.2.4.3.1 Market size and forecast, by Type
6.2.4.3.2 Market size and forecast, by Drug Therapy
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Type
6.3.3 Europe Market size and forecast, by Drug Therapy
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Market size and forecast, by Type
6.3.4.1.2 Market size and forecast, by Drug Therapy
6.3.4.2 France
6.3.4.2.1 Market size and forecast, by Type
6.3.4.2.2 Market size and forecast, by Drug Therapy
6.3.4.3 U.K.
6.3.4.3.1 Market size and forecast, by Type
6.3.4.3.2 Market size and forecast, by Drug Therapy
6.3.4.4 Italy
6.3.4.4.1 Market size and forecast, by Type
6.3.4.4.2 Market size and forecast, by Drug Therapy
6.3.4.5 Spain
6.3.4.5.1 Market size and forecast, by Type
6.3.4.5.2 Market size and forecast, by Drug Therapy
6.3.4.6 Rest of Europe
6.3.4.6.1 Market size and forecast, by Type
6.3.4.6.2 Market size and forecast, by Drug Therapy
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Type
6.4.3 Asia-Pacific Market size and forecast, by Drug Therapy
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 Japan
6.4.4.1.1 Market size and forecast, by Type
6.4.4.1.2 Market size and forecast, by Drug Therapy
6.4.4.2 China
6.4.4.2.1 Market size and forecast, by Type
6.4.4.2.2 Market size and forecast, by Drug Therapy
6.4.4.3 Australia
6.4.4.3.1 Market size and forecast, by Type
6.4.4.3.2 Market size and forecast, by Drug Therapy
6.4.4.4 India
6.4.4.4.1 Market size and forecast, by Type
6.4.4.4.2 Market size and forecast, by Drug Therapy
6.4.4.5 South Korea
6.4.4.5.1 Market size and forecast, by Type
6.4.4.5.2 Market size and forecast, by Drug Therapy
6.4.4.6 Rest of Asia-Pacific
6.4.4.6.1 Market size and forecast, by Type
6.4.4.6.2 Market size and forecast, by Drug Therapy
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Type
6.5.3 LAMEA Market size and forecast, by Drug Therapy
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Brazil
6.5.4.1.1 Market size and forecast, by Type
6.5.4.1.2 Market size and forecast, by Drug Therapy
6.5.4.2 South Africa,
6.5.4.2.1 Market size and forecast, by Type
6.5.4.2.2 Market size and forecast, by Drug Therapy
6.5.4.3 Saudi Arabia
6.5.4.3.1 Market size and forecast, by Type
6.5.4.3.2 Market size and forecast, by Drug Therapy
6.5.4.4 Rest of LAMEA
6.5.4.4.1 Market size and forecast, by Type
6.5.4.4.2 Market size and forecast, by Drug Therapy
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 Bayer AG
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 CSL Ltd. (CSL Behring)
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 F. Hoffmann-La Roche AG
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 Grifols, S.A
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 Medexus Pharmaceuticals Inc.
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 Novo Nordisk A/S
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 octapharma ag
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Pfizer Inc.
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 Swedish Orphan Biovitrum AB
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 Takeda Pharmaceuticals Company ltd
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments

 

ページTOPに戻る


 

Summary

The global hemophilia treatment market was valued at $12,764.8 million in 2021, and is projected to reach $26,905.2 million by 2031, registering a CAGR of 7.5% from 2022 to 2031.
Hemophilia is usually an inherited bleeding disorder, in which the blood does not clot properly. This can lead to spontaneous bleeding, followed by injuries or surgery. Blood contains many proteins called clotting factors, which can help stop the bleeding. People with hemophilia have low levels of factor VIII or factor IX. The severity of hemophilia that a person has is determined by the amount of factor in the blood. Hemophilia is caused by a mutation or change, in one of the genes, that provides instructions for making the clotting factor proteins needed to form a blood clot. There are two major types of hemophilia namely, hemophilia A and hemophilia B. The treatment of hemophilia involves replacement of missing blood clotting factor so that the blood can clot properly. This is done by infusion, in which the commercially prepared factor concentrates are administered through a vein. People with hemophilia can learn how to perform these infusions themselves so that they can stop bleeding episodes and, by performing the infusions on a regular basis can even prevent most bleeding episodes.

The major factors that drive the growth of the global hemophilia treatment market include, increase in the prevalence of hemophilia, technological advancements in the treatment of hemophilia, and favorable government initiatives for hemophilia management. In addition, increase in target population, increased diagnosis rate, and rise in the use of prophylactic treatment for hemophilia also propel the market growth. However, high cost of hemophilia treatment, lack of medicines of hemophilia, and serious adverse effects associated with plasma derived products are expected to restrict the market growth. Conversely, the rise in the awareness about hemophilia in developing countries provides lucrative opportunities for the growth of the market.
The hemophilia treatment market is segmented on the basis of type, drug therapy, and region. According to type, the market is divided into hemophilia A and hemophilia B. On the basis of drug therapy, the market is bifurcated into recombinant coagulation factor concentrates therapy, plasma derived coagulation factor concentrates therapy, non-factor replacement therapy, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include, Bayer AG, Pfizer, Inc., F. Hoffmann-La Roche AG, CSL Ltd., Takeda Pharmaceuticals Company Ltd., Novo Nordisk A/S, Grifols S.A., Swedish Orphan Biovitrium AB, Octapharma AG, and Medexus Pharmaceuticals Inc.

Key Benefits For Stakeholders
●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hemophilia treatment market analysis from 2021 to 2031 to identify the prevailing hemophilia treatment market opportunities.
●The market research is offered along with information related to key drivers, restraints, and opportunities.
●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
●In-depth analysis of the hemophilia treatment market segmentation assists to determine the prevailing market opportunities.
●Major countries in each region are mapped according to their revenue contribution to the global market.
●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
●The report includes the analysis of the regional as well as global hemophilia treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments
By Type
● Hemophilia A
● Hemophilia B
By Drug Therapy
● Recombinant coagulation factor concentrates therapy
● Plasma derived coagulation factor concentrates therapy
● Non-factor replacement therapy
● Others

By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ Germany
○ France
○ U.K.
○ Italy
○ Spain
○ Rest of Europe
● Asia-Pacific
○ Japan
○ China
○ Australia
○ India
○ South Korea
○ Rest of Asia-Pacific
● LAMEA
○ Brazil
○ South Africa,
○ Saudi Arabia
○ Rest of LAMEA

● Key Market Players
○ Bayer AG
○ CSL Ltd. (CSL Behring)
○ F. Hoffmann-La Roche AG
○ Grifols, S.A
○ Medexus Pharmaceuticals Inc.
○ Novo Nordisk A/S
○ octapharma ag
○ Pfizer Inc.
○ Swedish Orphan Biovitrum AB
○ Takeda Pharmaceuticals Company ltd



ページTOPに戻る


Table of Contents

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: HEMOPHILIA TREATMENT MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Hemophilia A
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Hemophilia B
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY
5.1 Overview
5.1.1 Market size and forecast
5.2 Recombinant coagulation factor concentrates therapy
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Plasma derived coagulation factor concentrates therapy
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Non-factor replacement therapy
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Others
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
CHAPTER 6: HEMOPHILIA TREATMENT MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Type
6.2.3 North America Market size and forecast, by Drug Therapy
6.2.4 North America Market size and forecast, by country
6.2.4.1 U.S.
6.2.4.1.1 Market size and forecast, by Type
6.2.4.1.2 Market size and forecast, by Drug Therapy
6.2.4.2 Canada
6.2.4.2.1 Market size and forecast, by Type
6.2.4.2.2 Market size and forecast, by Drug Therapy
6.2.4.3 Mexico
6.2.4.3.1 Market size and forecast, by Type
6.2.4.3.2 Market size and forecast, by Drug Therapy
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Type
6.3.3 Europe Market size and forecast, by Drug Therapy
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Market size and forecast, by Type
6.3.4.1.2 Market size and forecast, by Drug Therapy
6.3.4.2 France
6.3.4.2.1 Market size and forecast, by Type
6.3.4.2.2 Market size and forecast, by Drug Therapy
6.3.4.3 U.K.
6.3.4.3.1 Market size and forecast, by Type
6.3.4.3.2 Market size and forecast, by Drug Therapy
6.3.4.4 Italy
6.3.4.4.1 Market size and forecast, by Type
6.3.4.4.2 Market size and forecast, by Drug Therapy
6.3.4.5 Spain
6.3.4.5.1 Market size and forecast, by Type
6.3.4.5.2 Market size and forecast, by Drug Therapy
6.3.4.6 Rest of Europe
6.3.4.6.1 Market size and forecast, by Type
6.3.4.6.2 Market size and forecast, by Drug Therapy
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Type
6.4.3 Asia-Pacific Market size and forecast, by Drug Therapy
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 Japan
6.4.4.1.1 Market size and forecast, by Type
6.4.4.1.2 Market size and forecast, by Drug Therapy
6.4.4.2 China
6.4.4.2.1 Market size and forecast, by Type
6.4.4.2.2 Market size and forecast, by Drug Therapy
6.4.4.3 Australia
6.4.4.3.1 Market size and forecast, by Type
6.4.4.3.2 Market size and forecast, by Drug Therapy
6.4.4.4 India
6.4.4.4.1 Market size and forecast, by Type
6.4.4.4.2 Market size and forecast, by Drug Therapy
6.4.4.5 South Korea
6.4.4.5.1 Market size and forecast, by Type
6.4.4.5.2 Market size and forecast, by Drug Therapy
6.4.4.6 Rest of Asia-Pacific
6.4.4.6.1 Market size and forecast, by Type
6.4.4.6.2 Market size and forecast, by Drug Therapy
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Type
6.5.3 LAMEA Market size and forecast, by Drug Therapy
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Brazil
6.5.4.1.1 Market size and forecast, by Type
6.5.4.1.2 Market size and forecast, by Drug Therapy
6.5.4.2 South Africa,
6.5.4.2.1 Market size and forecast, by Type
6.5.4.2.2 Market size and forecast, by Drug Therapy
6.5.4.3 Saudi Arabia
6.5.4.3.1 Market size and forecast, by Type
6.5.4.3.2 Market size and forecast, by Drug Therapy
6.5.4.4 Rest of LAMEA
6.5.4.4.1 Market size and forecast, by Type
6.5.4.4.2 Market size and forecast, by Drug Therapy
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 Bayer AG
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 CSL Ltd. (CSL Behring)
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 F. Hoffmann-La Roche AG
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 Grifols, S.A
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 Medexus Pharmaceuticals Inc.
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 Novo Nordisk A/S
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 octapharma ag
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Pfizer Inc.
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 Swedish Orphan Biovitrum AB
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 Takeda Pharmaceuticals Company ltd
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

Allied Market Research社のその他分野での最新刊レポート

本レポートと同じKEY WORD(coagulation factor)の最新刊レポート


よくあるご質問


Allied Market Research社はどのような調査会社ですか?


アライドマーケットリサーチ(Allied Market Research)は世界の多様な市場に関する戦略や将来推計、成長/衰退予測、機会分析、消費者調査などを行い、市場調査レポートを積極的に出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/21 10:26

156.13 円

165.08 円

200.38 円

ページTOPに戻る